TY - JOUR
T1 - A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters
AU - Zhang, Bao Zhong
AU - Wang, Xiaolei
AU - Yuan, Shuofeng
AU - Li, Wenjun
AU - Dou, Ying
AU - Poon, Vincent Kwok Man
AU - Chan, Chris Chung Sing
AU - Cai, Jian Piao
AU - Chik, Kenn Ka Heng
AU - Tang, Kaiming
AU - Chan, Chris Chun Yiu
AU - Hu, Ye Fan
AU - Hu, Jing Chu
AU - Badea, Smaranda Ruxandra
AU - Gong, Hua Rui
AU - Lin, Xuansheng
AU - Chu, Hin
AU - Li, Xuechen
AU - To, Kelvin Kai Wang
AU - Liu, Li
AU - Chen, Zhiwei
AU - Hung, Ivan Fan Ngai
AU - Yuen, Kwok Yung
AU - Chan, Jasper Fuk Woo
AU - Huang, Jian Dong
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and in vivo protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.
AB - The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and in vivo protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.
KW - COVID-19
KW - linker-immunodominant site
KW - SARS-CoV-2
KW - spike protein
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85105818889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105818889&partnerID=8YFLogxK
U2 - 10.1080/22221751.2021.1921621
DO - 10.1080/22221751.2021.1921621
M3 - Article
C2 - 33890550
AN - SCOPUS:85105818889
SN - 2222-1751
VL - 10
SP - 874
EP - 884
JO - Emerging Microbes and Infections
JF - Emerging Microbes and Infections
IS - 1
ER -